Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Serina Therapeutics ( (SER) ) is now available.
On July 29, 2025, Serina Therapeutics announced the advancement of its drug candidate, SER-270, a VMAT2 inhibitor for tardive dyskinesia, coinciding with CEO Steve Ledger’s presentation at the BTIG Virtual Biotechnology Conference. This development highlights Serina’s strategic focus on innovative treatments for neurological conditions, potentially enhancing its market position and offering new therapeutic options for stakeholders.
The most recent analyst rating on (SER) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
The overall stock score for Serina Therapeutics reflects significant financial challenges, including substantial losses and negative cash flow, which are the most impactful factors. The bearish technical indicators and negative valuation metrics further weigh on the stock’s prospects. However, the recent breakthrough in LNP technology provides a positive aspect, potentially improving the company’s future strategic position.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutic drugs. The company specializes in POZ-conjugated drug candidates, targeting central nervous system disorders and other unmet medical needs.
Average Trading Volume: 17,172
Technical Sentiment Signal: Sell
Current Market Cap: $56.96M
For a thorough assessment of SER stock, go to TipRanks’ Stock Analysis page.